Ostarine (MK-2866)
os-TAR-een
Category
Compound type
Phase / Status
Development suspended by GTx/Johnson & Johnson in 2020. Phase 2 trials completed. Not FDA approved, but human data exists.
Standard Dose
Once daily
Half-life
Plasma elimination
Route(s)
Intramuscular, Subcutaneous or Oral
Research Stage
Research phase not specified; exercise appropriate caution.
Overview
Ostarine is described as a relatively mild SARM compared with some others. It is sometimes chosen for beginner-friendly research discussions and for supporting lean mass while dieting. It may still affect hormones and carries potential risks.
Plain-language summary
Ostarine is described as a relatively mild SARM compared with some others. It is sometimes chosen for beginner-friendly research discussions and for supporting lean mass while dieting. It may still affect hormones and carries potential risks.
Administration Routes
- Intramuscular
- Subcutaneous
- Oral
Also known as
Mechanisms
Selective Androgen Receptor Modulator (SARM) - binds to androgen receptors in muscle and bone and is designed to be more tissue-selective than some traditional anabolic steroids.
Detailed mechanism
Selective Androgen Receptor Modulator (SARM) - binds to androgen receptors in muscle and bone with intended selectivity, aiming to promote anabolic effects while minimizing impact on other tissues compared with traditional steroids.
Safety
Side effects
- Potential suppression of testosterone (dose- and duration-dependent)
- Possible changes to lipids (e.g., HDL reduction)
- Rare reports of liver enzyme elevation
- Headache at higher exposures
- Generally described as tolerable by some users, though safety data is not complete
Reported benefits
- May support lean mass and strength in some studies
- Fat-loss support is sometimes reported indirectly via diet
- Joint comfort is sometimes reported (varies)
- Oral administration
- Most discussed SARMs have differing levels of human data; Ostarine is among the better-studied
Safety profile
Limited human safety data beyond trial contexts. Use should be approached cautiously with monitoring when relevant.
Clinical trials
Research studies have been conducted in clinical contexts. It is not yet a broadly approved, routine medical therapy.
Structure
Verified structure
Ostarine (MK-2866)
No exact public structure match was confirmed, so the app will render a formula-backed illustration.
- Chemical Formula
- C22H16F3N3O2S
- Molecular Weight
- 441.46 g/mol
- CAS Number
- 2239728-63-1
Stack Context
Stacks with
Comparison context
Ostarine is often described as a milder, relatively well-studied SARM. Compared with other SARMs, users may report less suppression or less intensity, but hormone and safety effects are still possible. Experiences vary.
References
- 1View source
Selective androgen receptor modulators: current knowledge and clinical applications (Current Opinion in Pharmacology)
2010
- 2View source
Phase II study of enobosarm (GTx-024, S-22) in cancer-associated muscle wasting (Lancet Oncology)
2013
This profile summarizes research literature for education only. It is not medical advice, and it does not diagnose, treat, or recommend a dose. Consult a qualified professional before changing a protocol.